Disclosure The authors do not have any conflict of interest to declare related to topics discussed in this article. AP served in a consultant/advisory for Astra Zeneca, Agilent/Dako, Bristol-Myers Squibb, Lilly, Merck Sharp & Dohme and Roche Genentech. SP has received education grants, provided consultation, attended advisory boards, or provided lectures for Abbvie, Amgen, AstraZeneca, Bayer, Biocartis, Bioinvent, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F Hoffmann-La Roche, Foundation Medicine, Illumina, Janssen, Merck Sharp & Dohme, Merck Serono, Merrimack, Novartis, Pharma Mar, Pfizer, Regeneron, Sanofi, Seattle Genetics, Takeda and Vaccibody, from whom she has received honoraria (all fees to institution). TSKM reports a leadership position at Hutchinson China MediTech, AstraZeneca, Sanomics Limited, International Association for the Study of Lung Cancer, American Society of Clinical Oncology and Chinese Society of Clinical Oncology; stock ownership at Hutchinson China MediTech and Sanomics Limited; grants from AstraZeneca; personal fees from Boehringer Ingelheim; grants and personal fees from Roche/Genentech, Pfizer, Eli Lilly and Company, Merck Serono, Merck Sharp & Dohme, Novartis, SFJ Pharmaceuticals and Bristol-Myers Squibb; personal fees from Vertex, OncoGenex Pharmaceuticals, Celgene, Ignyta, Cirina, Fishawack Facilitate, Takeda Oncology, Janssen Pharmaceutica, Hutchinson China MediTech and GeneDecode; grants from Clovis Oncology and Xcovery LLC; and personal fees from OrigiMed, Hengrui Therapeutics, Inc., Sanofi-Aventis R&D, Yuhan Co., Ltd., prIME Oncology, Inc., Amoy Diagnostics, Loxo Oncology, Inc., ACEA Pharma, Boehringer Ingelheim, Eli Lilly and Company, Bristol-Myers Squibb, Genentech, Amgen and Spectrum Pharmaceuticals. TM has served in a consultant/advisory role for Astra Zeneca, Bristol-Myers Squibb, Eli-Lilly, Merck Sharp & Dohme, Chugai, Taiho, Ono, Novartis, Boehringer Ingelheim, Guardant and Roche Diagnostics; received honoraria from Astra Zeneca, Bristol-Myers Squibb, Eli-Lilly, Merck Sharp & Dohme, Chugai, Taiho, Ono, Novartis, Boehringer Ingelheim and Johnson & Johnson; and had grant support from Chugai, Taiho, Boehringer Ingelheim, Pfizer, Daiichi-Sankyo, Sanofi-Aventis and Ono. FdM served in a consultant/advisoryfor Astra Zeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Merck Sharp & Dohme, Novartis, Roche Genentech, Takeda and Pfizer. IA made no disclosures.